Skip to content

Subclinical Diabetes Confirmed by 75gm-OGTT Influence on the Prognosis of Decompensated Cirrhosis

Subclinical Diabetes Confirmed by 75gm-OGTT Influence on the Prognosis of Decompensated Cirrhosis

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04828512
Enrollment
1015
Registered
2021-04-02
Start date
2007-01-02
Completion date
2021-12-30
Last updated
2021-04-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Cirrhosis

Brief summary

Disorders of glucose metabolism, such as impaired glucose intolerance (IGT) and diabetes mellitus (DM), frequently occur in cirrhosis. However, it has been underestimated when fasting plasma glucose (FPG) levels are considered. We aimed to evaluate who needs to be undertaken a 75-g oral glucose tolerance test (OGTT) to find underlying subclinical diabetes.

Interventions

None listed

Sponsors

Yonsei University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Liver cirrhosis * Admitted to a hospital

Exclusion criteria

* Previously confirmed DM * Being treated for DM * Standard risk factors of T2DM, such as high body mass index and family history of diabetes * Symptoms of DM, such as increased thirst and the need to urinate * Either hepatocellular carcinoma or other malignancy * Hepatic failure or uncontrolled decompensation \[that is, refractory ascites or active variceal hemorrhage\] * Significant illnesses such as sepsis that may have interfered with glucose metabolism * Pancreatic dysfunction such as acute/chronic pancreatitis that may have affected glucose metabolism.

Design outcomes

Primary

MeasureTime frameDescription
Survivalthrough study completion, an average of 3 yearOverall survival

Secondary

MeasureTime frameDescription
major complications of cirrhosisthrough study completion, an average of 3 yearhepatic encephalopathy (HE), the development of spontaneous bacterial peritonitis (SBP), acute kidney injury (AKI), variceal bleeding, and infection

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 8, 2026